Main Article Content


Psoriasis is fundamentally an inflammatory skin condition with reactive abnormal epidermal differentiation and hyper-proliferation affecting 2-3% of world’s population. Pathophysiology of the disease includes mainly the activation and migration of T cells to the dermis triggering the release of cytokines (tumor necrosis factor-alpha TNF-alpha, in particular) which lead to the inflammation and the rapid production of skin cells. Considering the morbidity in psoriasis & loss of effectiveness of present treatment, psoriasis is screened in light of Kitibha disease (Kushtha) as mentioned by Acharya Charaka. The etiological factors, symptomatology, and complications of Kitibha compared with that of psoriasis, grand similarity was revealed. A preliminary randomized single blinded controlled clinical trial of drugs in 46 cases of psoriasis was conducted, to prove the practical approach of management of psoriasis. For this clinical study divided into following groups viz. Group A (10 cases were given 3 gm Daruharidra per day in 3 divided doses), group B (10 cases were provided 3 gm Kalmeg per day in 3 divided doses) and Group C (10 cases were given combination of both i.e.1g each per day in 3 divided doses), Group D (Placebo control group consisting of 8 patients were given wheat flour as 6 capsules in 3 divided doses) and Group E (Standard Controlled Group, having 8 patients who were administered with Methotrexate 7.5 mg once a week). The trial drugs were given for a period of three months to each patient. Controlled group was more effective (75%) as compared to combine group but reoccurrence was frequent in controlled group. Combined Group (A+ B) reveal 51% and Daruharidra reveals (40%) relief. When Daruharidra and Kalmeg are given alone give better result but when adding together has shown additive effect similar to standard control group Methotrexate.


Kitibha Psoriasis Hepatoprotective Drugs

Article Details

How to Cite
Sharma , S. K., Anshul, Sharma, . R., & Shukla, . G. D. . (2019). Role of hepatoprotective drugs in the management of skin disorders with special reference to Kitibha (psoriasis): A case study. Environment Conservation Journal, 20(SE), 1–6.


  1. Aromdee, C. 2012. Modifications of andrographolide to increase some biological activities: a patent review. Expert Opinion on Therapeutic Patents, 22:169-180.
  2. Chao, W.W. and Lin, B.F. 2010. Isolation and identification of bioactive compounds in Andrographis paniculata (Chuanxinlian). Chinese Medicine, 5:1-17.S
  3. Danielsen, K., Olsen, A.O., Wilsgaard, T and Furberg, A.S. 2013. Is the prevalence of psoriasis increasing? A 30–year follow-up of a population–based cohort, Br J Dermatol., 168:1303–10.
  4. Devaraj, S., Jegathambigai, R., Kumar, P., Sivaramakrishnan, S. 2010. A study on the hepatoprotective effect of Andrographis paniculata (Burm.F) Nees on mice. Journal of Phytology, 2: 25-30.
  5. Fuji, R., Mould, J.F.J., Tang, B., Brandt, H., Pomerantz, D., Chapnick, J. 2012. Burden of disease in patients withdiagnosed psoriasis in Brazil: results from 2011 national health and wellness survey (NHWS), Value Health., 15(4): A107.
  6. Gibbs, S. 1996. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol., 35(9): 633–9.
  7. Hsieh, Y.S., Kuo, W.H., Lin, T.W., Chang, H.R., Lin, T.H., Chen, P.N., Chu, S.C. 2007. Protective effects of berberine against low-density lipoprotein (LDL) oxidation and oxidized LDL-induced cytotoxicity on endothelial cells. J Agric Food Chem, 55(25): 10437-45.
  8. Kimball, A. B., Jacobson, C., Weiss, S., Vreeland, M.G., Wu, Y. 2005. The psychosocial burden of psoriasis. Am J Clin Dermatol, 6(6): 383–92.
  9. Lin, F.L. Wu, S.J., Lee, S.C. and Ng, L.T. 2009. Antioxidant, antioedema and analgesic activities of Andrographis paniculata extracts and their active constituent andrographolide. Phytotherapy Research, 23: 958-964.
  10. Parisi, R., Symmons, D.P.M., Griffiths, C.E.M., Ashcroft. D.M. 2013. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol,133(2): 377–85.
  11. Ronald, P., Lisa P. and Nussbaum, 2015. Nonalcoholic Fatty Liver Disease and Psoriasis What a Dermatologist Needs to Know, J Clin Aesthet Dermatol, 8(3): 43–45.
  12. Roy, D.N., Mandal, S., Sen, G., Mukhopadhyay, S. and Biswas, T., 2010. 14- Deoxyandrographolide desensitizes hepatocytes to tumour necrosis factor alpha- induced apoptosis through calcium-dependent tumour necrosis factor receptor superfamily member 1A release via the NO/cGMP pathway. British Journal of Pharmacology, 160: 1823-1843.
  13. Sharma, P.V. 2009. Dravyaguna Vigyan vol-II, Chaukhamba Bharti Academy ,Varansi ,Reprint, 544-545.
  14. Stern, R.S., Nijsten, T., Feldman, S.R., Margolis, D.J., Rolstad, T. 2004. Psoriasis is common, carries a substantial burden even when not extensive and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc, 9(2): 136–9.